At the J. P. Morgan Healthcare Conference, we presented our progress in advancing novel therapies for neuromuscular diseases, with CEO Thomas Holm Pedersen delivering the presentation. The presentation highlighted our first-in-class ClC-1 inhibitor, ignaseclant (formerly known as NMD670), our differentiated muscle biology platform, and the clinical development of programs in Charcot-Marie-Tooth disease, spinal muscular atrophy, and myasthenia gravis.